Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1959 1
1975 1
1977 1
1978 1
1983 2
1986 1
1987 2
1989 1
1990 2
1991 1
1992 2
1993 1
1994 2
1995 1
1996 1
1997 3
1998 4
1999 4
2000 4
2001 14
2002 11
2003 6
2004 18
2005 22
2006 32
2007 37
2008 50
2009 54
2010 51
2011 61
2012 74
2013 65
2014 75
2015 87
2016 105
2017 107
2018 88
2019 104
2020 125
2021 139
2022 134
2023 127
2024 44

Text availability

Article attribute

Article type

Publication date

Search Results

1,364 results

Results by year

Filters applied: . Clear all
Page 1
Short-term outcomes of intravitreal faricimab for treatment-naive neovascular age-related macular degeneration.
Matsumoto H, Hoshino J, Nakamura K, Nagashima T, Akiyama H. Matsumoto H, et al. Graefes Arch Clin Exp Ophthalmol. 2023 Oct;261(10):2945-2952. doi: 10.1007/s00417-023-06116-y. Epub 2023 May 17. Graefes Arch Clin Exp Ophthalmol. 2023. PMID: 37195339
PURPOSE: To investigate the efficacy and safety of loading phase treatment with 3 monthly intravitreal injections of faricimab for neovascular age-related macular degeneration (nAMD). METHODS: We retrospectively analyzed 16-week outcomes of 40 consecut …
PURPOSE: To investigate the efficacy and safety of loading phase treatment with 3 monthly intravitreal injections of faricimab for neovascul …
Personalized genetic counseling for Stargardt disease: Offspring risk estimates based on variant severity.
Cornelis SS, Runhart EH, Bauwens M, Corradi Z, De Baere E, Roosing S, Haer-Wigman L, Dhaenens CM, Vulto-van Silfhout AT, Cremers FPM. Cornelis SS, et al. Am J Hum Genet. 2022 Mar 3;109(3):498-507. doi: 10.1016/j.ajhg.2022.01.008. Epub 2022 Feb 3. Am J Hum Genet. 2022. PMID: 35120629 Free PMC article.
The risk for offspring of an STGD1-affected individual with the "severe|severe" genotype or a "severe|mild with complete penetrance" genotype to develop STGD1 at some moment in life was estimated at 2.8%-3.1% (1 in 36-32 individuals) and 1.6%-1.8% ( …
The risk for offspring of an STGD1-affected individual with the "severe|severe" genotype or a "severe|mild with complete penetrance" genotyp …
Factors That Can Prolong Ocular Treatment Duration in Age-Related Macular Degeneration.
Kaiser PK, Giani A, Fuchs H, Chong V, Heier JS. Kaiser PK, et al. Ophthalmic Res. 2023;66(1):653-663. doi: 10.1159/000527815. Epub 2023 Jan 10. Ophthalmic Res. 2023. PMID: 36626895 Free article. Review.
Intravitreal injections of anti-vascular endothelial growth factor (VEGF) agents are used to treat wet age-related macular degeneration (wAMD); however, they are associated with a considerable treatment burden and poor real-world outcomes. ...
Intravitreal injections of anti-vascular endothelial growth factor (VEGF) agents are used to treat wet age-related macular …
Beyond VEGF: Targeting Inflammation and Other Pathways for Treatment of Retinal Disease.
Muniyandi A, Hartman GD, Song Y, Mijit M, Kelley MR, Corson TW. Muniyandi A, et al. J Pharmacol Exp Ther. 2023 Jul;386(1):15-25. doi: 10.1124/jpet.122.001563. Epub 2023 May 4. J Pharmacol Exp Ther. 2023. PMID: 37142441 Free PMC article. Review.
Neovascular eye diseases include conditions such as retinopathy of prematurity, proliferative diabetic retinopathy, and neovascular age-related macular degeneration. Together, they are a major cause of vision loss and blindness worldwide. ...The affect …
Neovascular eye diseases include conditions such as retinopathy of prematurity, proliferative diabetic retinopathy, and neovascular age …
Diabetic macular oedema: evidence-based treatment recommendations for Asian countries.
Cheung GC, Yoon YH, Chen LJ, Chen SJ, George TM, Lai TY, Park KH, Tahija SG, Uy HS, Wong TY. Cheung GC, et al. Clin Exp Ophthalmol. 2018 Jan;46(1):75-86. doi: 10.1111/ceo.12999. Epub 2017 Jun 21. Clin Exp Ophthalmol. 2018. PMID: 28558152 Review.
Efficacy of anti-vascular endothelial growth factor therapy in diabetic macular oedema has been demonstrated in randomized controlled trials. ...Recent clinical trial data allow head-to-head comparisons between the different anti-vascular endothelial growth factor a …
Efficacy of anti-vascular endothelial growth factor therapy in diabetic macular oedema has been demonstrated in randomized con …
Emerging Treatment Modalities for Neovascular Age-Related Macular Degeneration: A Systematic Overview.
Balatsoukas DD, Tsaousis KT, Boboridis KG, Konstas AG, Topouzis F. Balatsoukas DD, et al. Adv Ther. 2022 Jan;39(1):5-32. doi: 10.1007/s12325-021-01949-7. Epub 2021 Nov 1. Adv Ther. 2022. PMID: 34724151 Review.
INTRODUCTION: Neovascular age-related macular degeneration (nAMD) represents a leading cause of irreversible visual loss affecting the quality of life of millions of elderly patients worldwide. ...Therefore, further innovative, long-term treatment opti …
INTRODUCTION: Neovascular age-related macular degeneration (nAMD) represents a leading cause of irreversible vis …
Age-related macular degeneration: using morphological predictors to modify current treatment protocols.
Ashraf M, Souka A, Adelman RA. Ashraf M, et al. Acta Ophthalmol. 2018 Mar;96(2):120-133. doi: 10.1111/aos.13565. Epub 2017 Nov 11. Acta Ophthalmol. 2018. PMID: 29130626 Free article. Review.
To assess predictors of treatment response in neovascular age-related macular degeneration (AMD) in an attempt to develop a patient-centric treatment algorithm. We conducted a systematic search using PubMed, EMBASE and Web of Science for prognostic ind …
To assess predictors of treatment response in neovascular age-related macular degeneration (AMD) in an attempt t …
Age-related macular degeneration: anti-vascular endothelial growth factor treatment.
Arnold JJ. Arnold JJ. BMJ Clin Evid. 2016 Feb 24;2016:0701. BMJ Clin Evid. 2016. PMID: 26909890 Free PMC article. Review.
INTRODUCTION: Sight-threatening (late) age-related macular degeneration (AMD) is found in about 1.4% of people of European ancestry aged 70 years, with prevalence increasing with age. ...METHODS AND OUTCOMES: We conducted a systematic ove …
INTRODUCTION: Sight-threatening (late) age-related macular degeneration (AMD) is found in about 1.4% of p …
Intractable Ocular Diseases and Treatment Progress.
Zhang X, Li S, Tang Y, Guo Y, Gao S. Zhang X, et al. AAPS PharmSciTech. 2020 Aug 14;21(6):236. doi: 10.1208/s12249-020-01774-1. AAPS PharmSciTech. 2020. PMID: 32803351 Review.
In recent years, with the aging of the population and the frequent use of electronic devices, many eye diseases have shown a linear upward trend, such as dry eye disease, glaucoma, cataract, age-related macular degeneration, and diabetic retinopathy. T …
In recent years, with the aging of the population and the frequent use of electronic devices, many eye diseases have shown a linear upward t …
"Do Not Do" recommendations for retinopathies: A mixed consensus study.
Pablo L, Beckford CA, Martin-Delgado J, Ferro Osuna M, Fernández-Ferreiro A, Fernández Rodriguez MI, Rodriguez Cid MJ, Méndez S, Torres A, Ignacio E, Mira JJ. Pablo L, et al. Arch Soc Esp Oftalmol (Engl Ed). 2021 Nov;96(11):578-586. doi: 10.1016/j.oftale.2021.01.007. Epub 2021 Oct 17. Arch Soc Esp Oftalmol (Engl Ed). 2021. PMID: 34756279 Review.
PURPOSE: Among the main causes of blindness and severe vision loss are age-related macular degeneration, diabetic macular oedema, and retinal vein occlusion. ...In the second phase, a retrospective observational study was conducted, by conductin …
PURPOSE: Among the main causes of blindness and severe vision loss are age-related macular degeneration, diabeti …
1,364 results